Medical News

RSS

Isis announces results from ISIS-TTRRx Phase 1 study on TTR amyloidosis

Isis Pharmaceuticals, Inc. announced today results from a Phase 1 study with ISIS-TTRRx. The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein.

6 Jan 2012

LCA calls for more aggressive integration of imaging advances and biomedical research

As the War on Cancer enters its fifth decade and the number of people being diagnosed with cancer continues to rise, Lung Cancer Alliance (LCA) called for more aggressive integration of advanced imaging technology and biomedical research to improve prevention, earlier detection and treatment of cancer.

6 Jan 2012

Royals designated hitter to receive 47th annual Hutch Award

Billy Butler, designated hitter for the Kansas City Royals, will receive the 47th annual Hutch Award. The award is given each year to a Major League Baseball player who best exemplifies the honor, courage and dedication of baseball great Fred Hutchinson, both on and off the field.

6 Jan 2012

Wake Forest Baptist participates in novel brain tumor vaccine clinical trial

A national clinical trial testing the efficacy of a novel brain tumor vaccine has begun at Wake Forest Baptist Medical Center, the only facility in the Southeast to participate.

6 Jan 2012

UCSD surgeons perform west coast's first ex-vivo liver resection

A team led by Alan Hemming, MD, transplant surgeon at UC San Diego Health System, has successfully performed the west coast's first ex-vivo liver resection, a radical procedure to completely remove and reconstruct a diseased liver and re-implant it without any tumors. The procedure saved the life of a 27-year old mother whose liver had been invaded by a painful tumor that crushed the organ and entangled its blood supply.

6 Jan 2012

Pfizer commences PF-05280602 Phase 1 trial in hemophilia A & B

Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced that Pfizer Inc. has initiated a Phase 1 clinical trial for PF-05280602, an investigational proprietary, engineered variant of recombinant human Factor VIIa developed by Catalyst Biosciences.

6 Jan 2012

Solar power can make hemodialysis treatments more environmentally friendly

Solar power can help offset high utility costs and make hemodialysis treatments more environmentally friendly, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

6 Jan 2012

Experts share 10 symptoms of cervical and other gynecologic cancers

Pelvic pain and abnormal bleeding aren't the only signs of gynecologic cancer. As part of Cervical Health Awareness Month in January, experts at The University of Texas MD Anderson Cancer Center share other symptoms that often are overlooked.

6 Jan 2012

New guideline on management of hyperglycemia in non-critically ill hospitalized patients

Hyperglycemia, or having high glucose levels in the blood, is a common, serious and costly health care problem in hospitalized patients. Today, The Endocrine Society released a clinical practice guideline (CPG) providing recommendations for practical and safe glycemic targets and describing protocols and system improvements required to achieve glycemic goals for hospitalized patients in a non-critical care setting.

6 Jan 2012

Essilor signs five new partnership agreements in North Africa, Latin America

Essilor has further expanded its presence in fast-growing markets by signing five new partnership agreements in North Africa and Latin America.

6 Jan 2012

New anti-tumor compounds show promise for hard-to-treat cancers

New anti-tumor compounds produced by Dr. Aleem Gangjee, Distinguished Professor of Medicinal Pharmacy at Duquesne University's Mylan School of Pharmacy, show such promise for fighting hard-to-treat tumors that the National Institutes of Health (NIH) has placed them on its fast track for development.

6 Jan 2012

Tetragenetics reports results from G-SOME H5N1 vaccine preclinical study

Tetragenetics Inc., a biotechnology company focused on the development of recombinant vaccines, today reported preclinical study results showing that an investigational nanoparticle-based influenza vaccine protects against a highly pathogenic H5N1 avian influenza strain.

6 Jan 2012

Two non-profit organizations to address critical shortage of funding for pediatric cancer research

Two non-profit organizations committed to eliminating cancer in children and young adults have joined together to address the critical shortage of funding for pediatric cancer research.

6 Jan 2012

New laboratory approach could aid brain recovery

In humans, active periods of the debilitating disease Multiple Sclerosis (MS) can last for mere minutes or extend to weeks at a time. They're caused by lesions in the brain that develop, partly heal, and then recur. Research into a cure has been difficult, because to date scientists have not been able to replicate these brain recurring symptoms in laboratory mice. That's frustrating because these lab animals, known as animal "models," are the primary tool for research into the mechanisms and potential treatments for MS.

6 Jan 2012

Colorful food fare is more appealing to children than adults

Parents of picky eaters can encourage their children to eat more nutritionally diverse diets by introducing more color to their meals, according to a new Cornell University study. The study finds that colorful food fare is more appealing to children than adults. Specifically, food plates with seven different items and six different colors are particularly appealing to children, while adults tend to prefer fewer colors only three items and three colors.

6 Jan 2012

FSU, First Signs and Autism Speaks introduce new treatment section of Video Glossary

Autism Speaks, the world's largest autism science and advocacy organization, together with First Signs, a leader in educating parents and professionals about the early signs of autism and related disorders, and Florida State University's Autism Institute today announced the launch of a new treatment section of its acclaimed online Autism Video Glossary, giving parents an important new tool as they work to determine the best treatment options for their child.

6 Jan 2012

Researchers identify potential target for schistosomiasis vaccine

In the complicated life cycle of ancient flatworms that cause schistosomiasis, Case Western Reserve University researchers have identified a gene activator crucial to development of the parasites within humans - a potential target for a vaccine.

6 Jan 2012

Lawsuit alleges hospice co. improperly pushed patients through nursing homes; N.Y. prosecutor investigates hospital practices

Kaiser Health News reports that a lawsuit unsealed this week alleges that a national hospice company committed Medicare fraud by improperly cycling patients through nursing homes. In the meantime, a N.Y. prosecutor is investigating a hospital's management practices.

6 Jan 2012

Combination of cancer drugs shows promise against Pompe disease

Kids with Pompe disease fail because of a missing enzyme, GAA, that leads to dangerous sugar build-up, which affects muscles and movement. An enzyme replacement treatment pioneered at Duke University has saved many lives, but some children with Pompe disease produce an immune reaction that blocks the benefits of the life-saving enzyme treatment.

6 Jan 2012

AstraZeneca plans to progress Targacept's AZD1446 as treatment for AD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that AstraZeneca has informed the company that it plans to progress the development of Targacept's product candidate AZD1446 as a treatment for Alzheimer's disease.

5 Jan 2012